Travere Therapeutics
Stock Forecast, Prediction & Price Target
Travere Therapeutics Financial Estimates
Travere Therapeutics Revenue Estimates
Travere Therapeutics EBITDA Estimates
Travere Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $227.49M N/A | $212.01M -6.80% | $145.23M -31.49% | Avg: $324.97M Low: $261.88M High: $511.92M avg. 123.75% | Avg: $449.98M Low: $374.05M High: $632.10M avg. 38.46% | Avg: $434.72M Low: $361.37M High: $610.67M avg. -3.39% | Avg: $547.09M Low: $454.77M High: $768.52M avg. 25.84% |
Net Income
% change YoY
| $-180.09M N/A | $-278.48M -54.63% | $-111.39M 59.99% | Avg: $-145.44M Low: $-175.27M High: $18.56M avg. -30.56% | Avg: $-6.69M Low: $-89.12M High: $146.30M avg. 95.39% | Avg: $33.91M Low: $26.47M High: $51.76M avg. 606.23% | Avg: $94.81M Low: $74.01M High: $144.70M avg. 179.56% |
EBITDA
% change YoY
| $-137.28M N/A | $-244.31M -77.96% | $-326.24M -33.53% | Avg: $-217.63M Low: $-342.82M High: $-175.38M avg. 33.29% | Avg: $-301.34M Low: $-423.31M High: $-250.49M avg. -38.46% | Avg: $-291.13M Low: $-408.96M High: $-242.00M avg. 3.39% | Avg: $-366.38M Low: $-514.66M High: $-304.55M avg. -25.84% |
EPS
% change YoY
| -$3.01 N/A | -$4.37 -45.18% | -$1.5 65.67% | Avg: -$1.62 Low: -$2.36 High: $0.25 avg. -8.32% | Avg: $0.08 Low: -$1.2 High: $1.97 avg. 105.02% | Avg: $0.46 Low: $0.36 High: $0.7 avg. 459.16% | Avg: $1.28 Low: $1 High: $1.95 avg. 179.56% |
Operating Expenses
% change YoY
| $360.21M N/A | $455.98M 26.58% | $521.92M 14.46% | Avg: $304.60M Low: $245.47M High: $479.83M avg. -41.63% | Avg: $421.77M Low: $350.60M High: $592.48M avg. 38.46% | Avg: $407.47M Low: $338.72M High: $572.39M avg. -3.39% | Avg: $512.80M Low: $426.27M High: $720.35M avg. 25.84% |
FAQ
What is Travere Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 212.65% in 2025-2028.
We have gathered data from 10 analysts. Their low estimate is -175.27M, average is -145.44M and high is 18.56M.
What is Travere Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 46.16% in 2025-2028.
We have gathered data from 13 analysts. Their low revenue estimate is $261.88M, average is $324.97M and high is $511.92M.
What is Travere Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 183.85% in 2025-2028.
We have gathered data from 10 analysts. Their low earnings per share estimate is -$2.36, average is -$1.62 and high is $0.25.
What is the best performing analyst?
In the last twelve months analysts have been covering Travere Therapeutics stock. The most successful analyst is Liisa Bayko.